1K0 Stock Overview
A clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IGM Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.50 |
| 52 Week High | US$16.60 |
| 52 Week Low | US$4.26 |
| Beta | 0.19 |
| 11 Month Change | -42.18% |
| 3 Month Change | -4.49% |
| 1 Year Change | 80.08% |
| 33 Year Change | -81.03% |
| 5 Year Change | -58.44% |
| Change since IPO | -48.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1K0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.8% | -0.7% | 0.2% |
| 1Y | 80.1% | -17.2% | 8.5% |
Return vs Industry: 1K0 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 1K0 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 1K0 volatility | |
|---|---|
| 1K0 Average Weekly Movement | 16.7% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 1K0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1K0's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 198 | Mary Harler | igmbio.com |
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
IGM Biosciences, Inc. Fundamentals Summary
| 1K0 fundamental statistics | |
|---|---|
| Market cap | €503.68m |
| Earnings (TTM) | -€209.47m |
| Revenue (TTM) | €2.78m |
191.6x
P/S Ratio-2.5x
P/E RatioIs 1K0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1K0 income statement (TTM) | |
|---|---|
| Revenue | US$2.92m |
| Cost of Revenue | US$184.38m |
| Gross Profit | -US$181.46m |
| Other Expenses | US$38.38m |
| Earnings | -US$219.84m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.70 |
| Gross Margin | -6,218.71% |
| Net Profit Margin | -7,534.03% |
| Debt/Equity Ratio | 0% |
How did 1K0 perform over the long term?
See historical performance and comparison